Cyclacel Pharmaceuticals Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
All right, I want to thank everyone for joining us. I'm Kevin DeGeeter with Oppenheimer. The next presenting Company is Cyclacel. Joining us are the Company's CEO, Spiro Rombotis; and Company's CFO, Paul McBarron. And we're going to structure this primarily as a Q&A format. But maybe before we jump in, Spiro or Paul, maybe you can give us the 90-second overview of Cyclacel and the Company's two lead programs.
Thank you, Kevin. And thank you, the Oppenheimer team for inviting us to share our thoughts at this year's conference. As many of you who have been following the Company know, Cyclacel is an oncology-focused company. We have two drugs in development that are now in mid-stage development: fadra, long name is fadraciclib, a CDK2/9 inhibitor; and 140 or CYC140, our PLK1 inhibitor.
We recently started enrolling in the Phase 1/2 study for fadra, which actually if successful, will lead to a registration enabling outcome. This is in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
